nox-e36
Nucleic acidexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00976729)
Timeline
Indications
Mechanism of action
- C-C motif chemokine 2INHIBITOR
CCL2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- nox-e36
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01547897 | Phase 2 | Mar 1, 2012 | Noxxon AG |
| NCT01372124 | Phase 1 | Jun 1, 2011 | InnoPharma, Noxxon AG |
| NCT01085292 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2010 | Noxxon AG, Profil GmbH |
| NCT00976729 | Phase 1 | May 1, 2009 | Noxxon AG |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Noxxon AG | For profit | 4 | 4 | 2 | 2009 |
| InnoPharma | For profit | 1 | 0 | 1 | 2011 |
| Profil GmbH | For profit | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1